You are here: Industry Insights > cystic fibrosis

News List

Patients call for end to CF drug price row at key meeting pharmaphorum
September 27, 2018
Representatives of NHS England and cystic fibrosis drug company Vertex are to meet on Thursday to try and resolve a two-year impasse over access to life-changing medications.
FDA Approves Kalydeco americanpharmaceuticalreview
August 17, 2018
Vertex Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved Kalydeco (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane con
NICE suspends review of Vertex’s Symkevi for cystic fibrosis pharmaceutical-technology
August 14, 2018
The UK’s National Institute for Health and Care Excellence (NICE) has suspended its review of Vertex Pharmaceuticals’ cystic fibrosis (CF) drug Symkevi (tezacaftor/ivacaftor) after the company failed to submit evidence to NICE regarding the clinical and c
FDA approves Vertex’s cystic fibrosis therapy Orkambi for children under six pharmaceutical-technology
August 10, 2018
The US Food and Drug Administration (FDA) has granted approval to Vertex Pharmaceuticals for the use of its Orkambi (lumacaftor/ivacaftor) medicine to treat cystic fibrosis in children between two and five years old.
Boehringer joins consortium to develop new cystic fibrosis gene therapies pharmatimes
August 07, 2018
Boehringer Ingelheim has partnered with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis
Celtaxsys’ cystic fibrosis drug reduces lung exacerbations in phase 2 study fiercebiotech
August 03, 2018
Celtaxsys’ oral anti-inflammatory drug for cystic fibrosis, acebilustat, cleared a phase 2 study by demonstrating meaningful improvements in pulmonary exacerbations.......
Lung cell discovery opens new route for cystic fibrosis treatment fiercebiotech
August 02, 2018
Scientists already know cystic fibrosis is caused by mutations in the gene they call cystic fibrosis transmembrane conductance regulator (CFTR), but they didn’t know where expression of the gene is active in the body.
MPs call on government to help with Orkambi debate pharmatimes
July 23, 2018
MPs are calling on NHS England and Vertex to come to an agreement over the price of cystic fibrosis drug Orkambi.
Vertex mulls over NHS England’s offer for CF drugs pharmatimes
July 19, 2018
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condi
Vertex, NHS England no closer to Orkambi settlement pharmatimes
July 10, 2018
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.

Previous page 1 2 3 4 5 6 Next page